23andMe Holding Co. reported significant financial challenges in its Q3 FY25 results, highlighting ongoing liquidity concerns and the need for additional capital to sustain operations. The company ...

Further, 23andMe believes it is helpful in highlighting trends in its operating results because it excludes items that are not indicative of 23andMe’s core operating performance. In particular ...

Ancestry, for example, sells access to historical records that provide additional genealogical information. One of 23andMe’s main offerings has been health information — but this has drawn ...

These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ ...

These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to ...

There also needs to be better regulation of the accuracy and reliability of results provided by genetic testing companies. One of the most troubling examples of this is 23andMe’s testing for the ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.

with which we work to process a customer's sample and deliver their results, customer information will not be shared with any other entity unless they provide us with consent to do so," a 23andMe ...

SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human ...

23andMe's stock plummeted after a 2023 data breach exposed millions of customer accounts. The struggling genetic-testing company 23andMe has been quietly exploring a possible sale of its ...

Genetic testing firm 23andMe (NASDAQ:ME) said it formed a special board committee to review strategic alternatives. The special committee will look at options including a sale, business ...

The genetic testing company 23andMe has agreed to pay $30 million to American plaintiffs to settle a lawsuit over a data breach last year that specifically targeted customers of Ashkenazi Jewish ...